SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic

REACT-2 is a large-scale community study of SARS-CoV-2 seroprevalence in England. Here, the authors estimate that 6% of adults in England had been infected by mid-July 2020, with health and long-term care workers and those of Black or South Asian ethnicity disproportionately affected.

Guardado en:

Detalles Bibliográficos
Autores principales:	Helen Ward, Christina Atchison, Matthew Whitaker, Kylie E. C. Ainslie, Joshua Elliott, Lucy Okell, Rozlyn Redd, Deborah Ashby, Christl A. Donnelly, Wendy Barclay, Ara Darzi, Graham Cooke, Steven Riley, Paul Elliott
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/7dfcdf6279114b1688ba398d2a7a06ce
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7dfcdf6279114b1688ba398d2a7a06ce
record_format	dspace
spelling	oai:doaj.org-article:7dfcdf6279114b1688ba398d2a7a06ce2021-12-02T13:30:15ZSARS-CoV-2 antibody prevalence in England following the first peak of the pandemic10.1038/s41467-021-21237-w2041-1723https://doaj.org/article/7dfcdf6279114b1688ba398d2a7a06ce2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-21237-whttps://doaj.org/toc/2041-1723REACT-2 is a large-scale community study of SARS-CoV-2 seroprevalence in England. Here, the authors estimate that 6% of adults in England had been infected by mid-July 2020, with health and long-term care workers and those of Black or South Asian ethnicity disproportionately affected.Helen WardChristina AtchisonMatthew WhitakerKylie E. C. AinslieJoshua ElliottLucy OkellRozlyn ReddDeborah AshbyChristl A. DonnellyWendy BarclayAra DarziGraham CookeSteven RileyPaul ElliottNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Helen Ward Christina Atchison Matthew Whitaker Kylie E. C. Ainslie Joshua Elliott Lucy Okell Rozlyn Redd Deborah Ashby Christl A. Donnelly Wendy Barclay Ara Darzi Graham Cooke Steven Riley Paul Elliott SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic
description	REACT-2 is a large-scale community study of SARS-CoV-2 seroprevalence in England. Here, the authors estimate that 6% of adults in England had been infected by mid-July 2020, with health and long-term care workers and those of Black or South Asian ethnicity disproportionately affected.
format	article
author	Helen Ward Christina Atchison Matthew Whitaker Kylie E. C. Ainslie Joshua Elliott Lucy Okell Rozlyn Redd Deborah Ashby Christl A. Donnelly Wendy Barclay Ara Darzi Graham Cooke Steven Riley Paul Elliott
author_facet	Helen Ward Christina Atchison Matthew Whitaker Kylie E. C. Ainslie Joshua Elliott Lucy Okell Rozlyn Redd Deborah Ashby Christl A. Donnelly Wendy Barclay Ara Darzi Graham Cooke Steven Riley Paul Elliott
author_sort	Helen Ward
title	SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic
title_short	SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic
title_full	SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic
title_fullStr	SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic
title_full_unstemmed	SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic
title_sort	sars-cov-2 antibody prevalence in england following the first peak of the pandemic
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7dfcdf6279114b1688ba398d2a7a06ce
work_keys_str_mv	AT helenward sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic AT christinaatchison sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic AT matthewwhitaker sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic AT kylieecainslie sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic AT joshuaelliott sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic AT lucyokell sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic AT rozlynredd sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic AT deborahashby sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic AT christladonnelly sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic AT wendybarclay sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic AT aradarzi sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic AT grahamcooke sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic AT stevenriley sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic AT paulelliott sarscov2antibodyprevalenceinenglandfollowingthefirstpeakofthepandemic
_version_	1718392924688875520

SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic

Ejemplares similares